B
BeOne Medicines AG (ONC)
NMS – Real vaqt narxi. Valyuta: USD
279.89
+4.55 (1.65%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
279.89
0.00 (0.00%)
Bozordan keyin: Jun 26, 2026, 4:10 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
279.89
+4.55 (1.65%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
279.89
0.00 (0.00%)
Bozordan keyin: Jun 26, 2026, 4:10 PM EDT
BeOne Medicines AG, onkologiya kompaniyasi, Qo'shma Shtatlar, Xitoy, Yevropa va xalqaro miqyosda saraton bemorlari uchun turli xil davolash usullarini kashf qilish va ishlab chiqish bilan shug'ullanadi. Kompaniyaning tijorat bosqichidagi mahsulotlari orasida turli qon saratonlarini davolash uchun Brutonning Tirozin Kinazining (BTK) kichik molekulyar ingibitori bo'lgan BRUKINSA; turli qattiq o'smalar va qon saratonlarini davolash uchun PD-1 ga qarshi antitel immunoterapiyasi TEVIMBRA; ko'p markazli Castleman kasalligi bo'lgan kattalar bemorlarini davolash uchun SYLVANT; menopauzadan oldingi va perimenopauzali ayollarda BC va saraton bilan kasallangan bemorlar uchun BAITUOWEI; va turli qattiq o'smalarni davolash uchun PARTRUVIX mavjud. Uning klinik bosqichidagi mahsulotlari orasida Bcl-2 ning kichik molekulyar ingibitori bo'lgan Sonrotoclax BGB-11417; yovvoyi turdagi va mutant BTK ga qarshi faol bo'lgan BTK ni nishonga oluvchi ximera degradasyon aktivasyon birikmasi BGB-16673; EGFR ga nishonlangan CDAC BG-60366; MAT2A ingibitori BG-89894 (SYH2039); MTA-kooperativ PRMT5 ingibitori BGB-58067; anti-EGFRxMET trispesifik antitel BG-T187 va BG-C0902; HPK-1 ingibitori BGB-26808; anti-B7H3 ADC BGB-C354; bispesifik HER2 ni nishonga oluvchi antitel Zanidatamab; anti-FGFR2b ADC BG-C137; Pan-KRAS ingibitori BGB-53038; anti-GPC3x4-1BB bispesifik antitel BGB-B2033; anti-MUC1xCD16A bispesifik antitel BGB-B3227; anti-CEAADC BG-C477; CDK4 ingibitori BGB-43395; CDK2 ingibitori BG-68501; anti-B7H4 ADC BG-C9074; Bcl-2 ingibitori BGB-21447; va IRAK4 ni nishonga oluvchi CDAC BGB-45035 mavjud. Shuningdek, kompaniyada turli xil preklinik dasturlar mavjud. Kompaniya Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical va Novartis bilan shartnomalarga ega. Kompaniya ilgari BeiGene, Ltd. nomi bilan tanilgan va 2025-yil may oyida BeOne Medicines AG nomini o'zgartirgan. BeOne Medicines AG 2010-yilda tashkil etilgan va Bazelda (Shveysariya) joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Xiaodong Wang Ph.D. | Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder |
| Mr. Aaron Rosenberg | Chief Financial Officer |
| Mr. Chan Lee | General Counsel, Senior VP & Corporate Secretary |
| Mr. Graham Hardiman | Global Head of Human Resources |
| Mr. John V. Oyler | Co-Founder, Executive Chairman & CEO |
| Mr. Luo Lusong Ph.D. | Head of External Innovation & Senior VP |
| Mr. Marcello Damiani | Chief Technology Officer |
| Mr. Titus B. Ball | VP & Chief Accounting Officer |
| Ms. Eleanor Duff Ph.D. | Senior VP & Head of Corporate Communications |
| Ms. Liza Heapes | Head of Investor Relations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-26 | 8-K | bgne-20260626.htm |
| 2026-06-11 | S-8 | tm2615922d1_s8.htm |
| 2026-06-11 | 8-K | bgne-20260611.htm |
| 2026-05-15 | 8-K | bgne-20260513.htm |
| 2026-05-06 | S-3ASR | tm2612881d1_s3asr.htm |
| 2026-05-06 | 8-K | bgne-20260506.htm |
| 2026-05-06 | 10-Q | bgne-20260331.htm |
| 2026-04-28 | DEFA14A | tm261479d6_defa14a.htm |
| 2026-04-28 | DEF 14A | tm261479-4_def14a.htm |
| 2026-04-28 | ARS | tm262811d2_ars.pdf |